Why Does Medical Device Registration in Latin America Often Get Delayed?

Why Does Medical Device Registration in Latin America Often Get Delayed?

Companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation baseline, then assess technical files, quality system, labeling, local agent requirements, clinical evidence, and post-market maintenance. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid delays caused by unclear classification, documentation, or authorization arrangements. For Chinese medical device companies, a reliable approach is to first perform product classification and documentation gap analysis, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Key Summary

The question of why Latin American registration takes longer often arises from multiple factors: incomplete classification, inconsistent evidence, inadequate local agent arrangements, and lack of a strategic multi-country approach. AIMEILI advises companies to treat this as part of a broader GHWP member state and multi-country access strategy, using a reusable core technical documentation package to support localizations rather than starting from scratch for each country.

Applicable Scenarios and Core Issues

Companies searching for this topic are typically looking not for a conceptual explanation but for practical guidance on whether their existing documentation can support a target market application, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect their launch plan. These concerns often involve product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities. For companies planning to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America, a country-by-country approach is insufficient. Instead, they should first create a reusable version of core technical files, quality system certificates, performance validation, clinical evidence, and labeling, then customize according to each country's regulatory requirements.

Registration Judgment Logic

Companies must first confirm the product's intended use, mechanism of action, usage scenario, mode of human contact, duration of use, sterility, power source, software or IVD characteristics, and then determine the risk class and submission pathway. A misstep in pathway selection will lead to errors in translation, notarization, authorization, testing, and supplementary documentation. For target market projects, it is essential to clarify the applicant and local liability boundaries: who holds the certificate, who communicates with regulators, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. Ambiguities in business contracts can later affect market control.

Documentation and Evidence

Common documents include product description, model matrix, intended use, risk classification justification, ISO 13485 or applicable quality system certificate, technical files, performance validation reports, risk management files, clinical evaluation or clinical evidence, labeling, authorization letters, existing registration certificates, manufacturer declarations, and post-market surveillance documentation. The key to document quality is not quantity but consistency. Label claims, test report coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application information must align. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on the number of files uploaded.

Common Mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local liability relationships.
• Directly translating NMPA documents without reorganizing evidence according to the target market pathway.
• Including too many models without adequate test reports, clinical evidence, or labeling coverage.
• Selecting a local agent solely based on sales cooperation without defining regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies among labels, instructions for use, promotional materials, and registration documentation, leading to corrections or post-market compliance risks.
• Failing to plan for multi-country document reuse, resulting in redundant efforts and increased costs and timelines for each country.

Company Preparation Checklist

Before initiating a project, companies should use an internal checklist to confirm the documentation baseline and avoid discovering critical evidence gaps after submission.

• Compile target product list, model matrix, and intended use statements.
• Review existing NMPA, CE, FDA, or other market registration documents for reusability.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English labeling.
• Define local agent or authorized representative responsibilities, costs, certificate control, and exit mechanisms.
• Create a target country gap assessment table specifying content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI recommends that companies view target market registration not as a one-time document submission but as a market access project. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first, then converting per country requirements, is generally faster, more stable, and facilitates future changes and renewals compared to compiling documents ad hoc for each country.

From a project management perspective, the three most critical control points are: (1) correct product classification and pathway determination; (2) consistency of the documentation evidence chain; and (3) clear regulatory liability boundaries with local partners. If these three areas are unclear, even a large volume of documentation may result in iterative corrections, agent communication delays, and post-market maintenance issues.

Common Follow-up Questions

Can domestic documents be directly used for target market registration?
Domestic documents can serve as a foundation but typically cannot be submitted as-is. Companies must adjust document structure, language, labeling, authorization documents, and evidence chains according to local regulatory requirements.

When is the best time to initiate a gap assessment?
Immediately after confirming the target market and product list. The sooner the gap assessment is completed, the easier it is to arrange supplementary testing, translation, labeling adjustments, and agent selection.

Why does the choice of local agent affect registration quality?
The local agent usually handles registration communication, changes, renewals, and post-market event management. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Implementation Recommendations

Companies should establish a project tracking table that includes product list, model specifications, registration pathway, document responsible persons, translation status, testing status, local agent communication records, and expected submission dates. This helps identify document gaps in a timely manner and allows management to assess whether the project will impact launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should be established to clarify which documents serve as core evidence and which must be reissued or supplemented per country. In particular, labeling, clinical evaluation, risk management, performance validation, and quality system certificates must maintain version consistency.

• Confirm target market and product list.
• Complete risk classification and pathway determination.
• Create a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators typically check for consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the product being applied for, or if the production address, model specifications, and labeling version differ from test reports, even extensive documentation may require supplementary explanations. Companies should create an evidence consistency checklist before submission, mapping product name, model, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling version, and quality system certificate. This fundamental step significantly reduces the likelihood of corrections, particularly for multiple GHWP member state projects or simultaneous submissions for multiple product families.

Localization Conversion and Agent Responsibilities

Target market registration often involves arrangements for local agents, authorized representatives, importers, or registration holders. Companies must confirm whether the local partner is responsible only for document submission or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability. Labeling and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative details, and after-sales contact information. For companies with existing CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than creating an entirely new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration does not end regulatory compliance. Companies must also manage certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, labeling versions, and regulatory update records. Many companies invest heavily in the registration phase but neglect post-market maintenance, leading to disconnects between certificates and market sales when production address changes, model expansions, labeling updates, or agent replacements occur. AIMEILI recommends incorporating this into an annual international registration plan: first define target market priorities, then build a reusable documentation package and country gap list, and finally schedule submissions, corrections, post-market maintenance, and renewal milestones. This approach not only improves single-country registration efficiency but also enables companies to develop a replicable overseas compliance capability, reducing costs each time they enter a new market.

This content is based on AIMEILI’s registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be guided by the latest requirements of the target country regulatory authority and product documentation.